HIV-tuberculosis coinfection: Difference between revisions

From IDWiki
()
()
 
Line 12: Line 12:
 
*Regimens that minimize drug-drug interactions:
 
*Regimens that minimize drug-drug interactions:
 
**[[Efavirenz]] 600 mg PO daily or [[raltegravir]] 400 mg PO bid, combined with [[abacavir]]/[[lamivudine]] or [[tenofovir disoproxil fumarate]]/[[emtricitabine]]
 
**[[Efavirenz]] 600 mg PO daily or [[raltegravir]] 400 mg PO bid, combined with [[abacavir]]/[[lamivudine]] or [[tenofovir disoproxil fumarate]]/[[emtricitabine]]
**[[tenofovir disoproxil fumarate]]/[[emtricitabine]] + [[efavirenz]]
+
**[[Tenofovir disoproxil fumarate]]/[[emtricitabine]] + [[efavirenz]]
**[[tenofovir disoproxil fumarate]]/[[emtricitabine]] + double [[raltegravir]]
+
**[[Tenofovir disoproxil fumarate]]/[[emtricitabine]] + double [[raltegravir]]
 
**[[Abacavir]]/[[lamivudine]] with BID [[dolutegravir]]
 
**[[Abacavir]]/[[lamivudine]] with BID [[dolutegravir]]
 
**[[Tenofovir alafenamide]] may or may not be affected by [[rifampin]]
 
**[[Tenofovir alafenamide]] may or may not be affected by [[rifampin]]

Latest revision as of 14:49, 5 January 2022

Management

Latent Tuberculosis Infection

Active Tuberculosis